ANNEXON, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 179.66K shares.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 61.31K shares, a 42.20% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 151.16K shares, a 13.47% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 1.29K shares, a 98.80% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 195.57K shares, a 48.82% decline from fiscal 2024.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 382.12K shares, a 396.99% increase from fiscal 2023.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 76.89K shares, a 400.44% increase from fiscal 2022.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 15.36K shares, a 96.07% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 179.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 393.42K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 61.31K shares 10-Q · filed 2026-05-07 | 213.76K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 151.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 195.57K shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 1.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 177.62K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 283.80K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 43.11K shares 10-Q · filed 2025-05-12 | 319.71K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 133.22K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 382.12K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 107.47K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 269.91K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 35.91K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 162.44K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 105.53K shares 10-Q · filed 2024-05-13 | 126.81K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 21.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 76.89K shares 10-K · filed 2024-03-26 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 59.78K shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 283.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 68.54K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 55.60K shares 10-Q · filed 2023-05-08 | 68.26K shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 3.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 15.36K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 8.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 197.10K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 236.32K shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 2.71K shares 10-Q · filed 2022-05-09 | 319.13K shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 185.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 391.35K shares 10-K · filed 2022-03-01 |
| 2021-09-30 | 47.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 205.72K shares derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | 82.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | 167.26K shares derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | 74.93K shares 10-Q · filed 2021-05-17 | 84.46K shares derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 9.53K shares 10-K · filed 2021-03-25 |
| 2020-09-30 | 9.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | |
| 2020-06-30 | 0.00 shares 10-Q · filed 2021-08-16 | |
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |